1. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5(5):621–3.
2. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014 Dec 8. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf . Accessed 21 Jun 2016.
3. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009 Oct 19–23. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf . Accessed 21 Jun 2016.
4. US Food and Drug Administration. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009: guidance for industry. 2015 Apr. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm444661.pdf . Accessed 28 Jul 2016.
5. Taylor L. Over 700 biosimilars now in development worldwide: report. 2014 Sep 30. http://www.pharmatimes.com/article/14-09-30/over_700_biosimilars_now_in_development_worldwide_report.aspx#ixzz3flma1lfd . Accessed 19 Jul 2016.